- Clinuvel Pharmaceuticals (CUV) has received approved registration from the Therapeutic Goods Administration (TGA) for its Scenesse drug
- Scenesse used in the prevention of skin irritation in adult patients with erythropoietic protoporphyria (EPP)
- EPP is an inherited disorder which causes burns and internal damage to vessels when patients are exposed to light
- Scenesse is a photo-protective drug which acts as an anti-oxidative, strengthens blood vessels, and reduces swelling
- It will also available as a prescription medication and will be administered by trained and accredited healthcare professional every two months
- Clinuvel has ended the day 1.55 percent in the red with shares trading for $21.61 each
Clinuvel Pharmaceuticals: Receives TGA approval for Scenesse
